Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents.
about
Ivabradine, coronary artery disease, and heart failure: beyond rhythm controlCardioprotection during cardiac surgeryAdvances in the management of heart failure: the role of ivabradineDirect inhibition, but indirect sensitization of pacemaker activity to sympathetic tone by the interaction of endotoxin with HCN-channels.Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.Risk-benefit assessment of ivabradine in the treatment of chronic heart failureCoordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of diseaseComparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditisChronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression.Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?Arrhythmogenic effect of sympathetic histamine in mouse hearts subjected to acute ischemiaPrognostic value of resting heart rate on cardiovascular and renal outcomes in type 2 diabetic patients: a competing risk analysis in a prospective cohortNebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive ratsEffect of adrenergic agonists on coronary blood flow: a laboratory study in healthy volunteers.Endothelium-derived endothelin-1The cardiovascular physiology and pharmacology of endothelin-1.Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillationEffectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice.The Protective Effects of Ivabradine in Preventing Progression from Viral Myocarditis to Dilated Cardiomyopathy.In silico coronary wave intensity analysis: application of an integrated one-dimensional and poromechanical model of cardiac perfusion.Vascular endothelial ageing, heartbeat after heartbeat.Working under pressure: coronary arteries and the endothelin system.Heart rate reduction in cardiovascular disease and therapy.Heart rate: a forgotten link in coronary artery disease?Cardioprotection by ivabradine through heart rate reduction and beyond.Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.Pleiotropic effects of dronedarone on ischemia/reperfusion injury in heart and brain.Is heart rate a treatment target in heart failure?Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation.Ivabradine: potential clinical applications in critically ill patients.'Inappropriate' sinus tachycardia: does the 100 beats per min cut-off matter?Heart rate as a possible therapeutic guide for the prevention of cardiovascular disease.Treatment of Myocardial Ischemia/Reperfusion Injury by Ischemic and Pharmacological Postconditioning.Ivabradine: Heart Failure and Beyond.Cardiac and Hemodynamic Benefits: Mode of Action of Ivabradine in Heart Failure.Heart rate and its reduction in chronic heart failure and beyond.Ivabradine for the treatment of chronic heart failure.Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon.
P2860
Q26865770-172940CB-63F1-4D7E-A338-549B64082197Q26866366-BE783A17-4DF7-41FE-8F3C-A18805E71AD3Q28072418-A7D48BE1-7D1C-4AA3-AF22-09BDFF48F7A3Q30316590-1CD71D1D-0C20-465E-8BE7-9359DBC4DF1CQ30316766-8EB3F72B-D1B8-4E1E-A75D-F9CF61D12EE5Q30318221-6F0E302F-1399-4236-91CE-BDB029B089FAQ33568592-AF8470CA-A1D8-4BCD-AEAF-0CD04534F716Q33870879-863C093E-F79A-4353-A99D-DACF7E06C4D2Q34326097-AA7CEFE3-D782-4657-8A2D-A5E5F40C2DDAQ34722763-FF6A2B48-F76C-4EEF-A0A8-9A2D144C929EQ35286339-A03683E2-7237-407B-921B-BDEB59567168Q35719014-B291293E-979C-4C73-A62E-1DA12359CB37Q36249527-2E076FA3-4C0A-4EA7-9451-580B1306FE7CQ36596813-A1E48299-CDC8-471A-B932-7C9BA98D48E6Q36949423-6AA32102-9D7C-4437-8090-03403FAB7D90Q36958421-E078EE07-7CB7-4BD2-8AFF-AB44DA78CCCFQ36958430-9DBA39E6-117B-4CAF-9B42-51BAF8CD7BACQ37106753-E7A1DBF7-D353-478C-8A13-E16CAEC5CCB2Q37250491-08F650C7-7443-4A54-A805-250A9F693CF4Q37383105-AB28B4EA-EE9D-4B82-8DDD-A4B9588342C8Q37410175-3128A668-4900-4DA8-B9E2-B03B8F46A4A3Q37545073-0BDCFB23-425A-4426-83A9-2F45351FECD3Q37710927-834BA144-167D-4603-85F6-D8E87857CBECQ37784463-E0D2FC1A-B274-4A62-B1AC-610E9DC4E96CQ37868929-FB39D71E-A91C-4B66-BA1A-C007CDB26CC1Q37912844-47F32D7F-6AF5-4552-8296-99A2261BC779Q37923966-EBC7EFD6-647B-41B3-BD4B-878F7D3D41CCQ37988319-2BF7DA4C-43FC-4654-A55C-C3306C6315BCQ37992528-C27AC505-7F28-4E9B-B212-D0771C291811Q38025390-29406282-80E3-4FCB-A0E1-EE71C9325F8EQ38052022-9C8316EC-E22A-44FF-A9BF-5A0825673570Q38086846-D95431AB-EAD2-4461-8273-92EB56C8314DQ38130624-32B31E88-66D1-4B81-81DA-D4E6CDDC74A8Q38542449-29C9BD8C-6471-413E-85D1-6560AE172884Q38546764-934102B5-06DC-4882-924F-8C39996BD404Q38621386-D7CA83AA-DDBE-4EC8-81B0-046A38122996Q38669556-3ACB59AD-5BF8-433E-B2BE-089105E65B51Q38769814-BBF9CF07-92CD-485B-92E4-B43DB33C5CD4Q38797276-DD6AFD76-27A1-4150-A780-54F66D78B884Q38842008-6236194E-C514-4E90-9868-D19EB7B62ED7
P2860
Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heart rate in the pathophysiol ...... selective bradycardic agents.
@en
Heart rate in the pathophysiol ...... selective bradycardic agents.
@nl
type
label
Heart rate in the pathophysiol ...... selective bradycardic agents.
@en
Heart rate in the pathophysiol ...... selective bradycardic agents.
@nl
prefLabel
Heart rate in the pathophysiol ...... selective bradycardic agents.
@en
Heart rate in the pathophysiol ...... selective bradycardic agents.
@nl
P2860
P356
P1476
Heart rate in the pathophysiol ...... selective bradycardic agents.
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0707673
P407
P577
2008-01-28T00:00:00Z